Search Result

Results for "

CPI

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Adenosine Receptor (2) Apoptosis (2) Bacterial (1) CD73 (1) Epigenetic Reader Domain (4) Fungal (1) Histone Acetyltransferase (2) Histone Demethylase (3) Histone Methyltransferase (3) Isotope-Labeled Compounds (1) Itk (1) Mitochondrial Metabolism (1) PROTACs (1)
By Research Areas:	Cancer (21) Infection (2) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123419

CPI-4203	Histone Demethylase	Cancer
CPI-4203 is a potent KDM5A inhibitor with an IC₅₀ of 250 nM. CPI-4203 is competitive with 2-oxoglutarate (2-OG). CPI-4203 is structurally related to CPI-455 (HY-100421) but is less potent .

HY-100376

CPI-1189
CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases .

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-134899

CPI-1328

Histone Methyltransferase Cancer

CPI-1328 is an EZH2 inhibitor with a K_i value of 63 fM.
HY-111085

CPI-905

Histone Methyltransferase Cancer

CPI-905 is a potent, selective, and cell-active EZH2 inhibitor .

CPI-1328	Histone Methyltransferase	Cancer
CPI-1328 is an EZH2 inhibitor with a K_i value of 63 fM.

CPI-905	Histone Methyltransferase	Cancer
CPI-905 is a potent, selective, and cell-active EZH2 inhibitor .

HY-100421

CPI-455 5 Publications Verification	Histone Demethylase	Cancer
CPI-455 is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-100421A

CPI-455 hydrochloride	Histone Demethylase	Cancer
CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-15846

CPI-203 4 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC₅₀ value of appr 37 nM (BRD4 α-screen assay).

HY-150298

Soquelitinib CPI-818	Itk	Inflammation/Immunology Cancer
Soquelitinib (CPI-818) is a highlyl selective covalent ITK inhibitor. Soquelitinib decreases DNA replication and cell cycle signaling .

HY-15453

Devimistat 5+ Cited Publications CPI-613	Apoptosis Mitochondrial Metabolism	Cancer
Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-12863

Pelabresib CPI-0610	Epigenetic Reader Domain	Cancer
Pelabresib (CPI-0610) is a potent, selective, orally active and cell-active BET inhibitor. Pelabresib inhibits BRD4-BD1 with an IC₅₀ of 39 nM, and with an EC₅₀ value of 0.18 μM for MYC .

HY-120196

CPI703

Epigenetic Reader Domain Cancer

CPI703, a BRD inhibitor, binds with residues in domain1 of 5DBM complex .

CPI703	Epigenetic Reader Domain	Cancer
CPI703, a BRD inhibitor, binds with residues in domain1 of 5DBM complex .

HY-100482

CPI-637 Maximum Cited Publications 11 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CPI-637 is a selective and potent CBP/EP300 bromodomain inhibitor with IC₅₀ values of 0.03 μM, 0.051 μM and 11.0 μM for CBP, EP300 and BRD4 BD-1, respectively, and an EC₅₀ of 0.3 μM for CBP .

HY-101978

Ciforadenant 5 Publications Verification CPI-444; V81444	Adenosine Receptor	Cancer
Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses .

HY-145602

Tulmimetostat CPI-0209	Histone Methyltransferase	Cancer
Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies .

HY-15453S

Devimistat-d10

CPI-613-d₁₀
Isotope-Labeled Compounds Cancer

Devimistat-d10 (CPI-613-d10) is the deuterium-labeled Devimistat (HY-15453) .

Devimistat-d10 CPI-613-d₁₀	Isotope-Labeled Compounds	Cancer
Devimistat-d10 (CPI-613-d10) is the deuterium-labeled Devimistat (HY-15453) .

HY-102024

A2A receptor antagonist 1 CPI-444 analog	Adenosine Receptor	Neurological Disease Cancer
A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A_2A receptor and A₁ receptor with K_i values of 4 and 264 nM, respectively .

HY-15846A

(Rac)-CPI-203

Others Cancer

(Rac)-CPI-203 is a racemate of CPI-203 (HY-15846) (BET bromodomain inhibitor)

*(Rac)-CPI-203*	Others	Cancer
(Rac)-CPI-203 is a racemate of CPI-203 (HY-15846) (BET bromodomain inhibitor)

HY-145386

*(S,S)-CPI-1612*	Others	Cancer
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-136285A

*(R,R)-CPI-1612*	Others	Cancer
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-109706

*(Rac)-CPI-098*	Bacterial Fungal	Infection
(Rac)-CPI-098 shows antibacterial activity. (Rac)-CPI-098 exhibits superior anti-fungal activity against Monascus ruber, better activity against Aspergillus fumigates, good activity against Aspergillus niger and Aspergillus parasites and moderate activity against Candida albicans .

HY-161250

*Pomalidomide-NH-PEG6-amide-C2-CPI-1612*	PROTACs	Cancer
Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC₅₀ of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .

HY-129379

DC0-NH2	ADC Cytotoxin	Cancer
DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component .

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P71229

	PPP1R14A Protein, Human (His) Protein Phosphatase 1 Regulatory Subunit 14A; 17 kDa PKC-Potentiated Inhibitory Protein of PP1; Protein Kinase C-Potentiated Inhibitor Protein of 17 kDa; CPI-17; PPP1R14A; CPI17; PPP1INL	Human	E. coli
	The PPP1R14A protein is a key cellular regulator that effectively inhibits PPP1CA and exhibits significant activity amplification upon phosphorylation. This phosphorylation-induced transformation turns PPP1R14A into a dynamic molecular switch adept at regulating PPP1CA substrate phosphorylation. PPP1R14A Protein, Human (His) is the recombinant human-derived PPP1R14A protein, expressed by E. coli , with C-6*His labeled tag. The total length of PPP1R14A Protein, Human (His) is 147 a.a., with molecular weight of 23-26 kDa.

HY-P70137

	Cystatin B/CSTB Protein, Mouse (His) rMuCystatin-B, His; CPI-B; CST6cystatin B (liver thiol proteinase inhibitor)10STFBcystatin-B; CSTB; cystatin B (stefinB); Cystatin B; EPM1; Liver thiol proteinase inhibitor; PME; Stefin B; stefin-B	Mouse	E. coli
	Cystatin B/CSTB Protein, an intracellular thiol proteinase inhibitor, crucially regulates proteolytic activities within the cell. By inhibiting thiol proteinases, Cystatin B maintains the balance of proteolytic processes, emphasizing its significance in cellular homeostasis. Its inhibitory function underscores involvement in cellular processes requiring precise regulation of proteolytic activity for normal cellular function and integrity. Cystatin B/CSTB Protein, Mouse (His) is the recombinant mouse-derived Cystatin B/CSTB protein, expressed by E. coli , with N-6*His labeled tag. The total length of Cystatin B/CSTB Protein, Mouse (His) is 98 a.a., with molecular weight of ~15.0 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Devimistat-d10
Devimistat-d10 (CPI-613-d10) is the deuterium-labeled Devimistat (HY-15453) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: